On Tuesday, Shares of PMC-Sierra Inc (NASDAQ:PMCS), gained 33.16% to $10.24.
Massachusetts-based Skyworks Solutions said Tuesday that it is acquiring Santa Clara’s PMC-Sierra for $2 billion in a deal that will assist it sell into the Big Data marketplace, according to Siliconbeat.
The deal is one of a wave of consolidation that has swept the semiconductor industry in the past few years.
PMC employs about 1,440 and designs and markets high-speed semiconductor networking chips.
Its shareholders will receive $10.50 in cash for each share of PMC common stock, a 37 percent premium to the company’s close on Monday.
Skyworks, which makes analog semiconductors for the automotive, cellular, home, industrial, smartphone and other markets, is financing the deal from cash on hand and debt. Siliconbeat Reports
PMC-Sierra, Inc. (PMC) is a semiconductor and software solution innovator transforming networks that connect, move, and store Big Data. The Company designs, develops, markets and supports semiconductor, embedded software, and board level solutions.
Shares of Cemex SAB de CV (ADR) (NYSE:CX), inclined 1.09% to $7.43, during its last trading session.
Cemex SAB de CV, declared that, after reaching close to 7 million beneficiaries through its social programs, it has set the aim of benefiting more than 10 million people by the year 2020. CEMEX made the declaration during the United Nations Private Sector Forum 2015 meetings held in New York City, attended by Fernando A. Gonzalez, Chief Executive Officer of CEMEX.
CEMEX supports infrastructure and housing development in the communities where it operates. Among its efforts, it is establishing community centers for construction training and education and empowering customers at the bottom of the socio-economic pyramid through different self-construction assistance initiatives, such as renowned Patrimonio Hoy and Assisted Self-Construction Integrated Program (PIAC).
CEMEX is working alongside organizations such as Habitat for Humanity, the Inter-American Development Bank, and the Clinton Global Initiative to achieve this ambitious aim.
CEMEX, S.A.B. de C.V. (CEMEX) is an operating and holding company engaged, directly or indirectly, through its operating subsidiaries, primarily in the production, distribution, marketing and sale of cement, ready-mix concrete, aggregates, clinker and other construction materials throughout the world, and that provides construction-related services to customers and communities in more than 50 countries throughout the world.
Shares of SanDisk Corporation (NASDAQ:SNDK), inclined 2.98% to $61.24, during its last trading session. The stock’s 50-day moving average is $53.34 and its 200-day moving average is $61.58. SanDisk has a 52 week low of $44.28 and a 52 week high of $106.64. The stock has a market capitalization of $12.52 billion and a price-to-earnings ratio of 23.93.
SanDisk Corporation’s SVP Yehoshua Nir sold 1,125 shares of the stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $60.00, for a total value of $67,500.00. Following the completion of the transaction, the senior vice president now directly owns 3,762 shares of the company’s stock, valued at $225,720. The sale was revealed in a filing with the SEC.
SanDisk Corporation provides flash storage solutions. The Company designs, develops and manufactures data storage solutions in a variety of form factors using flash memory, controller, firmware and software technologies.
Finally, Baxalta Inc (NYSE:BXLT), ended its last trade with -3.40% loss, and closed at $31.26.
Baxalta, and Momenta Pharmaceuticals, Inc. (MNTA), recently declared the initiation of a pivotal clinical trial in patients with chronic plaque psoriasis for M923, a biosimilar version of HUMIRA® (adalimumab). The trial is a randomized, double blind, active control, multi-center, global study in patients with chronic plaque psoriasis to compare the safety, efficacy and immunogenicity of M923 with HUMIRA. The companies are targeting first regulatory submission in 2017 and a first commercial launch in 2018.
Chronic plaque psoriasis is the most common form of psoriasis that affects one to three percent of the general population. It is characterized by scaly plaques or lesions on the body and the scalp, which may itch or sting, and can bleed when injured. Though there are treatments available, there is no cure for psoriasis.
This milestone is part of a global partnership between Baxalta and Momenta to develop and commercialize M923. With this collaboration, Baxalta leverages its leading clinical development, biologic manufacturing expertise, and global commercial capabilities, while Momenta provides its expertise in high-resolution analytics, characterization, clinical and regulatory strategy for complex products, and product and process development.
Baxalta Incorporated is a biopharmaceutical company. The Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
